Prediction of human pharmacokinetics and tissue distribution of apicidin, a potent histone deacetylase inhibitor, by physiologically based pharmacokinetic modeling

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 2, 2011, Pages 465-475

  Shin, Beom Soo ^a   Bulitta, Jürgen B ^b   Balthasar, Joseph P ^c   Kim, Minki ^d   Choi, Yohan ^d   Yoo, Sun Dong ^d  

^a Catholic University of Daegu   (South Korea)

^b ORDWAY RESEARCH INSTITUTE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d Sungkyunkwan University   (South Korea)

Author keywords

Apicidin; Human prediction; Pharmacokinetics; Physiologically based models; Tissue distribution

Indexed keywords

APICIDIN;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL BLOOD; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG MUSCLE LEVEL; DRUG PENETRATION; DRUG TISSUE LEVEL; HEART; IN VITRO STUDY; KIDNEY; LUNG; MALE; MATHEMATICAL MODEL; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RAT; SMALL INTESTINE; SPECIES DIFFERENCE; SPLEEN; STEADY STATE; STOMACH; TESTIS; TISSUE DISTRIBUTION; VENOUS BLOOD;

ANIMALS; ANTINEOPLASTIC AGENTS; FUSARIUM; HALF-LIFE; HISTONE DEACETYLASE INHIBITORS; HUMANS; INJECTIONS, INTRAVENOUS; LIVER; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED ICR; MODELS, BIOLOGICAL; PEPTIDES, CYCLIC; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; TISSUE DISTRIBUTION;

EID: 79960905075     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1502-y     Document Type: Article

References (25)

1. PA Marks VM Richon RA Rifkind 2000 Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells J Natl Cancer Inst 92 1210 1216 10922406 10.1093/jnci/92.15.1210 1:CAS:528:DC%2BD3cXlvFyhsb8%3D (Pubitemid 30627729)
2. PT Meinke P Liberator 2001 Histone deacetylase: a target for antiproliferative and antiprotozoal agents Curr Med Chem 8 211 235 11172676 1:CAS:528:DC%2BD3MXhtVSgt74%3D (Pubitemid 32416448)
3. PA Marks VM Richon RA Rifkind 2000 Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells J Natl Cancer Inst 92 1210 1216 10922406 10.1093/jnci/92.15.1210 1:CAS:528:DC%2BD3cXlvFyhsb8%3D (Pubitemid 30627729)
4. PA Konstantinopoulos GP Vandoros AG Papavassiliou 2006 FK228 (depsipeptide): a HDAC inhibitor with pleitropic antitumor activities Cancer Chemother Pharmacol 58 711 715 16435156 10.1007/s00280-005-0182-5 1:CAS:528:DC%2BD28Xns1SmsL4%3D (Pubitemid 44167398)
5. OH Krämer M Göttlicher T Heinzel 2001 Histone deacetylase as a therapeutic target Trends Endocrin Metab 12 294 300 10.1016/S1043-2760(01)00438- 6 (Pubitemid 33714220)
6. SJ Darkin-Rattray AM Gurnett RW Myers PM Dulski TM Crumley JJ Allocco C Cannova PT Meinke SL Colletti MA Bednarek SB Singh MA Goetz AW Dombrowski JD Polishook DM Schmatz 1996 Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase Proc Natl Acad Sci USA 93 13143 13147 8917558 10.1073/pnas.93.23.13143 1:CAS:528:DyaK28XmvV2qtrk%3D (Pubitemid 26382783)
7. JW Han SH Ahn SH Park SY Wang GU Bae DW Seo HK Kwon S Hong HY Lee YW Lee HW Lee 2000 Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and Gelsolin1 Cancer Res 60 6068 6074 11085529 1:CAS:528:DC%2BD3cXotV2lsLs%3D
8. SH Kwon SH Ahn YK Kim GU Bae JW Yoon S Hong HY Lee YW Lee HW Lee JW Han 2002 Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells J Biol Chem 277 2073 2080 11698395 10.1074/jbc.M106699200 1:CAS:528:DC%2BD38XosFemtA%3D%3D (Pubitemid 34968790)
9. H Park JY Im J Kim WS Choi HS Kim 2008 Effects of apicidin, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells Int J Mol Med 21 325 333 18288380 1:CAS:528: DC%2BD1cXjslWitb0%3D (Pubitemid 351330484)
10. JH Noh JH Song JW Eun JK Kim KH Jung HJ Bae HJ Xie JC Ryu YM Ahn SJ Wee WS Park JY Lee SW Nam 2009 Systemic cell-cycle suppression by apicidin, a histone deacetylase inhibitor, in MDA-MB-435 cells Int J Mol Med 24 205 226 19578794 1:CAS:528:DC%2BD1MXpsV2gtLs%3D
11. SH Kim S Ahn JW Han HW Lee HY Lee YW Lee MR Kim KW Kim WB Kim S Hong 2004 Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials Biochem Biophys Res Commun 315 964 970 14985106 10.1016/j.bbrc.2004.01.149 1:CAS:528:DC%2BD2cXhsFWmu7s%3D (Pubitemid 38249397)
12. S Pluemsampant OS Safronova K Nakahama I Morita 2008 Protein kinase CK2 is a key activator of histone deacetylase in hypoxia-associated tumors Int J Cancer 122 333 341 17935135 10.1002/ijc.23094 1:CAS:528:DC%2BD2sXhsVOnsrvI (Pubitemid 350234719)
13. BS Shin HS Chang EH Park CH Yoon HY Kim J Kim JK Ryu OP Zee KC Lee D Cao SD Yoo 2006 Pharmacokinetics of a novel histone deacetylase inhibitor, apicidin, in rats Biopharm Drug Dispos 27 69 75 16299816 10.1002/bdd.485 1:CAS:528:DC%2BD28Xjt1Ohu74%3D
14. BS Shin EH Park CH Yoon J Kim OP Zee SD Yoo 2005 In vitro investigation of the hepatic intrinsic clearance of apicidin, a histone deacetylase inhibitor, in mouse, rat, and human with correlation by nonspecific protein binding J Toxicol Environ Health A 68 2207 2218 16326434 10.1080/15287390500181992 1:CAS:528:DC%2BD2MXht1Kgtr3J (Pubitemid 41755677)
15. I Mahmood 2009 Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation J Pharm Sci 98 3850 3861 19177515 10.1002/jps.21682 1:CAS:528:DC%2BD1MXhtVKhsrzN
16. V Karalis L Claret A Iliadis P Macheras 2001 Fractal volume of drug distribution: it scales proportionally to body mass Pharm Res 18 1056 1060 11496945 10.1023/A:1010965001162 1:CAS:528:DC%2BD3MXlsV2itbg%3D (Pubitemid 32799955)
17. IA Nestorov LJ Aarons PA Arundel M Rowland 1998 Lumping of whole-body physiologically based pharmacokinetic models J Pharmacokinet Biopharm 26 21 46 9773391 1:CAS:528:DyaK1cXmsVGqu7s%3D (Pubitemid 28429460)
18. GML Meno-Tetang H Li S Mis N Pyszczynski P Heining P Lowe WJ Jusko 2006 Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4- octylphenyl)ethyl]propane-1, 3-diol hydrochloride) in rats after oral and intravenous doses Drug Metab Dispos 34 1480 1487 16751263 10.1124/dmd.105.009001 1:CAS:528:DC%2BD28Xpt1Sks7o%3D (Pubitemid 44285388)
19. HW Ruelius 1987 Extrapolation from animals to man: predictions, pitfalls and perspectives Xenobiotica 17 255 265 3554785 10.3109/00498258709043936 1:CAS:528:DyaL2sXitVOjsb8%3D (Pubitemid 17039289)
20. JS Park KR Lee JC Kim SH Lim JA Seo YW Lee 1999 A hemorrhagic factor (apicidin) produced by toxic Fusarium isolates from soybean seeds Appl Environ Microbiol 65 126 130 9872769 1:CAS:528:DyaK1MXjvVyhsQ%3D%3D
21. BS Shin J Kim CH Yoon CH Kim EH Park JW Han SD Yoo 2005 Development of a liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of apicidin, a novel histone deacetylase inhibitor, in rat serum: application to a pharmacokinetic study Rapid Commun Mass Spectrom 19 408 414 15645510 10.1002/rcm.1805 1:CAS:528:DC%2BD2MXhsVCjsb0%3D (Pubitemid 40203859)
22. A Bernareggi M Rowland 1991 Physiologic modeling of cyclosporin kinetics in rat and man J Pharmacokinet Biopharm 19 21 50 2023108 10.1007/BF01062191 1:CAS:528:DyaK3MXit1Sltbo%3D
23. RP Brown MD Delp SL Lindstedt LR Rhomberg RP Beliles 1997 Physiological parameter values for physiologically based pharmacokinetic models Toxicol Ind Health 13 407 484 9249929 1:CAS:528:DyaK2sXltl2itrk%3D (Pubitemid 27314117)
24. B Davies T Morris 1993 Physiological parameters in laboratory animals and humans Pharm Res 10 1093 1095 8378254 10.1023/A:1018943613122 1:STN:280:DyaK3szptFaqsg%3D%3D (Pubitemid 23211439)
25. DE Mager 2006 Quantitative structure-pharmacokinetic/pharmacodynamic relationships Adv Drug Deliv Rev 58 1326 1356 17092600 10.1016/j.addr.2006.08. 002 1:CAS:528:DC%2BD28Xht1CnsLzP